Faron Pharmaceuticals has recruited its first patient to a phase II clinical trial of its lead drug, Traumakine, in the treatment of organ failure after a ruptured abdominal aorta aneurysm
Faron Pharmaceuticals has recruited its first patient to a phase II clinical trial of its lead drug, Traumakine, in the treatment of organ failure after a ruptured abdominal aorta aneurysm